Table 1. Characteristics of Cambodian P. falciparum clinical isolates used to infect Anopheles species.
| Isolate | Population | K13 allele | Origin | Year | Parasite clearance half-life (h) | RSA0–3h survival rate (%) |
|---|---|---|---|---|---|---|
| KH001-027 | KH-C | WT | Ratanakiri | 2011 | 4.6 | ND |
| KH003-004 | KH-C | WT | Ratanakiri | 2011 | 1.6 | ND |
| KH003-010 | KH-C | WT | Ratanakiri | 2011 | 2.5 | ND |
| 967 | WKH-F02 | R539T | Pursat | 2010 | 6.0 | 48.9 |
| KH001-005 | WKH-F02 | R539T | Pursat | 2011 | 6.2 | ND |
| 957 | WKH-F02 | R539T | Pursat | 2010 | 6.9 | 28.1 |
| 887 | WKH-F04 | Y493H | Pursat | 2009 | 8.3 | 6.8 |
| 818-2 | WKH-F04 | Y493H | Pursat | 2010 | 8.0 | 3.5 |
| 829 | WKH-F03 | C580Y | Pursat | 2009 | 8.2 | ND |
ART, artemisinin; K13, kelch13; ND, not determined; RSA, Ring-stage Survival Assay; WT, wild type.
Three ART-sensitive parasites from a core population (KH-C) in Eastern Cambodia and six parasites from three ART-resistant founder populations (WKH-F02, WKH-F04 and WKH-F03) in Western Cambodia are listed. For each parasite, the K13 allele, province of origin, year of collection, parasite clearance half-life in patients and % survival value in the RSA0–3h in vitro are shown.